About Qureight

Muhunthan has over 20 years experience in thoracic medicine and is a board-certified Pulmonologist. He qualified as a doctor from Imperial College London and undertook specialist medical training in Oxford where he was appointed as a member of the Royal College of Physicians. He was awarded a PhD in Molecular Immunology from Imperial College London before being appointed as a consultant physician. He was previously Director of Interstitial Lung Diseases at Royal Papworth and Addenbrooke’s Hospitals Cambridge UK and is currently an Honorary Associate Professor at the University of East Anglia.

Patrick's extensive experience in leading finance and operations includes healthcare, biotech and engineering businesses in the UK and North America. His previous roles have included responsibility for building, managing and scaling all aspects of high-tech service, manufacturing, and research businesses from start-ups to listed companies, at VetCT Specialists, CN Bio Innovations and Johnson Matthey. Patrick holds a PhD in History from the University of Cambridge and is a Fellow of the ICAEW, having trained with Deloitte.

Rebecca is responsible for scaling company operations and ensuring sustainable growth at Qureight. She brings over 20 years of operational leadership across medical research and deep tech. Before joining Qureight, Rebecca served as COO at quantum computing company Riverlane, leading operational growth and helping raise over £100M in venture capital. Her founding executive experience at a healthcare innovation institute (THIS Institute) and senior advisory roles at the Danish Diabetes and Endocrine Academy mark her as a leader shaped by both medical innovation and cutting‑edge technology. With a PhD in Epidemiology from the University of Cambridge and an MBA (Distinction) from The Open University, Rebecca blends rigorous academic training with commercial acumen.

Steven has over 20 years of experience in healthcare and data science. As an undergraduate he studied Computer Science followed by Medicine at the University of Cambridge. He later went on to undertake academic and specialist training in Anaesthesia and Intensive Care Medicine, and is a Fellow of the Royal College of Anaesthetists. Steven has a longstanding passion for computational research in healthcare, with publications in the domain of critical care pathophysiology and surgical data science. Previous to Qureight, Steven was Head of Research and Strategy at CMR Surgical and Director of Clinical, Regulatory and AI at Flok Health, and brings with him a wealth of experience in building AI solutions in MedTech and HealthTech.

Jessica brings in-depth knowledge of the clinical imaging market and over 15 years of experience in the imaging sector. With a proven track record of driving growth from start-ups to AIM-listed organisations, she is focused on developing a high-performing commercial team, growing revenue, and expanding collaborations with scientific partners and global biopharmaceutical companies. Before joining Qureight, Jessica held senior roles at IXICO plc. She earned a BSc Hons in Biology from the University of Leeds.

Simon has over 19 years of experience in Radiology and is currently doing clinical work in London as a Consultant Thoracic Radiologist. He also holds a PhD in Biomedical Imaging, specialising in fibrotic lung diseases following his Fellowship at Royal Brompton and Harefield Hospital Foundation Trust. He was previously a Consultant Thoracic Radiologist at King’s Hospital Foundation Trust. He also has a background in computer science, specialising in machine learning and computer vision. His research focuses on advanced computational imaging analysis and digital biomarker discovery in diffuse lung diseases. He is the past Imaging Chair for the European Respiratory Society and in 2022 was elected to the Fleischner Society, a prestigious global group of leading Respiratory Scientists, Pulmonologists and Radiologists.

Darren has a wealth of experience in the software industry with a background in big data and distributed systems. His previous roles have included Head of Engineering at Autonomy and Director of Engineering, Big Data at Hewlett Packard Enterprise. He has developed software and managed teams from large multinationals to start-ups. He is experienced in growing technology infrastructure and teams from pre-seed stage through to product launch and beyond.

Debbie has over 20 years' experience leading strategic operations across healthcare, academia, and biotech. She is passionate about optimising business performance and driving growth by building best-in-class operational capabilities. She has a strong track record of delivering scalable, compliance frameworks that enhance customer experience, accelerate product development, and improve service delivery. Debbie holds a Masters in Natural Sciences from the University of Cambridge.

Claus is a C-suite leader with two decades of transformation and technology experience. With a proven track record of driving strategic planning, differentiation and optimisation, Claus is focused on building, leading and inspiring diverse teams that innovate and collaborate to achieve critical organisational goals. He currently serves as Chief Information and Technology Officer at the University of Texas Medical Centre and Dell Medical School, leading the innovation and technology elements of establishing a new Academic Medical Centre. Claus also hold an advisory role with Lifespace Communities, Inc.. He was awarded a PhD in Computer Science from Aarhus University, holds a Masters in Computer Science and Bachelors in Mathematics.

Xose is an internationally respected healthcare executive working at the intersection of technology and healthcare. With more than 25 years of professional experience, Xose is committed to advancing healthcare innovation and the strategic use of data to empower decision-making in precision medicine. He is currently Head of the Digital Oncology Network at IQVIA, where he leads the Digital Oncology Network, a pan-European initiative connecting 18 major hospitals to create a cutting-edge, federated and consent-driven cancer data ecosystem. Throughout his career, Xose has excelled at solving biological and data puzzles. Most recently, he served as the inaugural Chief Data Officer at the Institut Curie in Paris. Prior to this, his work took him to the European Bioinformatics Institute and later to Thermo Fisher Scientific, where we worked  as a bioinformatics consultant. Xose holds a PhD from the University of Oviedo, in Spain.  

Toby Maher is Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles.

Dr Maher has spent over 20 years specialising in the management of interstitial lung disease. Since June 2020 he has been Director of ILD at Keck Medicine of University of Southern California. He previously ran the ILD unit at Royal Brompton Hospital, London and was a Professor of ILD at Imperial College, London. His research interests include; biomarker discovery, cellular senescence in the pathogenesis of IPF and clinical trials. He has been involved in >100 trials in fibrotic lung disease from phase 1b through to phase 4 and including those assessing IPF, sarcoidosis, scleroderma, rheumatoid arthritis and inflammatory myositis. He is an associate editor for American Journal of Respiratory and Critical Care Medicine. He has authored over 400 papers on pulmonary fibrosis.

Dr Melissa Wickremasinghe is a Consultant Respiratory Physician at Imperial College Healthcare NHS Trust. She trained in respiratory medicine at the Royal Brompton Hospital, St Mary's Hospital and Hammersmith Hospital, London, and holds a PhD from Imperial College in transcriptional control mechanisms in Respiratory epithelial cell chemokine networks.

She founded the Interstitial Lung Disease unit at St Mary's Hospital which went on to achieve national commissioning status. Her clinical and research interests centre on the application of AI and digital health to transform ILD care. These include AI-assisted ILD diagnostics using multimodality inputs, remote monitoring for ILD, and the design of service delivery pathways enabled by digital healthcare.

Dr Wickremasinghe is an NIHR grant holder and has led a multi-centre UK study on remote monitoring in ILD. She has an interest in preventative healthcare behaviours and also early diagnostic approaches for interstitial lung disease. Her broader interests include health inequalities, patient engagement, and clinical informatics; she served as clinical lead for the ICHNT patient portal.

Outside medicine, she is the founder and director of the Medico Orchestra, a Trust orchestra bringing together healthcare professionals through music.

Phil is a Professor of Interstitial Lung Disease at Imperial College London and holds the Asthma + Lung UK Chair of Respiratory Research. He is a Consultant in Interstitial Lung Disease and Director of the NIHR Cardiorespiratory Clinical Research Facility at the Royal Brompton Hospital. He qualified from Guy’s, King’s and St Thomas’ School of Medicine in 2004, where he completed an intercalated BSc in Molecular Genetics. He trained at St Mary’s hospital as an NIHR academic clinical fellow in respiratory medicine and went on to undertake a PhD at Imperial College. Following completion of his clinical training in respiratory and critical care medicine he returned to Imperial College as a Senior Clinical Lecturer. He was awarded the Action for Pulmonary Fibrosis Mike Bray Fellowship which enabled him to establish his research group studying the interaction between the respiratory tract microbiota and innate immunity in pulmonary fibrosis. He now leads an active clinical and translational research programme, overseeing a multidisciplinary team of basic scientists and clinical trial staff focused on advancing the understanding and treatment of interstitial lung diseases.

Bill is a biopharmaceutical industry advisor with more than 25 years of experience in executive leadership, product development, medical affairs, and board director roles. He is Principal at Teton Bioscience and has provided drug development and strategic advisory services since 2015. He co-founded Indalo Therapeutics, a clinical-stage fibrosis company, served as a Board Director, and was Chief Medical Officer until 2020. He also served as Senior Vice President, Clinical Development at InterMune, Inc. (acquired by Roche) where he led the successful development of Esbriet® for Idiopathic Pulmonary Fibrosis and advanced a product development portfolio spanning a range of therapeutic areas. Earlier in his career, Bill held product development positions at Genentech (part of the Roche Group) and IntraBiotics Pharmaceuticals, and was an infectious disease specialist and researcher at the University of California San Francisco (UCSF). He currently serves on the Board of Directors at Endeavor BioMedicines and the Bluefield Project, recently served on the Boards of Virion Therapeutics and Hennepin Life Sciences, and is a member of multiple scientific advisory boards. Bill received his MD from the University of North Carolina School of Medicine and has a doctorate in epidemiology from University of California, Berkeley. Bill completed his internal medicine residency and infectious disease fellowship at UCSF.

Paul Ford, MD, PhD, is a UK-trained pulmonologist and drug development leader with deep expertise in translational medicine and fibrosis. He spent 10 years at Imperial College London in the laboratory of Prof. Sir Peter Barnes, leading his own research group focused on clinical translational studies in COPD. He also ran the specialist cough service and co-led the difficult asthma clinic with Prof. Barnes. After transitioning from academia in 2009, Dr. Ford held senior R&D roles across industry, including Translational Medicine Lead at Novartis, Chief Medical Officer at Galecto (Copenhagen), Head of Development and Fibrosis at Galapagos (Mechelen), and Head of Development at PureTech (Boston). He designed and led the first-in-human and early clinical programmes for multiple key assets, including GB0139 (Galecto), ziritaxestat and GLPG1205 (Galapagos), and LYT-100 (PureTech). He has overseen IPF trials involving nearly 2,000 patients, such as ISABELA 1 & 2, PINTA, and ELEVATE. Dr. Ford serves as a fractional CMO to several biotech companies, providing strategic and operational leadership across programmes in IPF, AATD, and Alport syndrome. He continues to design and run large registrational Phase 3 trials, as well as early-stage and ATMP-based studies, including secretome, gene therapy, and inhaled therapeutic approaches. He currently oversees a portfolio of > ten development programmes spanning discovery to late-stage clinical execution.

Pilar has over 15 years’ experience in clinical research and has been Principal and Chief Investigator in multiple studies and clinical trials. She currently works as a respiratory consultant (pulmonologist) with a sub-speciality in Interstitial Lung Diseases (ILDs) for Royal Devon and Exeter Hospital, where she is also the ILD Research Lead. Pilar was also recently appointed Associate Research and Development Director for Royal Devon University Healthcare NHS Foundation Trust. She runs one of the two dedicated Familial ILD Services in the UK and she is the Secretary of Group 12.04 for Rare ILD of the European Respiratory Society (ERS). She is a Member of the British Thoracic Society Specialist Advisory Group (BTS SAG) for Interstitial & Rare Lung Disease. Pilar has chaired the ILD working group of the Respiratory Effectiveness Group (REG) since 2022. Pilar earned her Primary Medical Qualification / MD degree at the National University of San Marcos in 2004 and worked as a researcher and collaborator professor at the Faculty of Medicine of the University of Navarra until 2015.

Javier has over 15 years of experience at the intersection of AI, software engineering and healthcare, and is focused on turning foundational research into real-world impact. He was formerly Senior Principal Science Manager at Microsoft and led the Multimodal AI team at Microsoft Health Futures UK, developing and scaling cutting-edge AI systems to improve patient outcomes across radiology, pathology and clinical care. Javier has led projects including InnerEye, assistive AI for cancer treatment, which was deployed across the NHS to accelerate radiotherapy by automating CT scan planning and segmentation, and MAIRA, a multimodal AI agent for radiology report generation. He also led Microsoft’s collaboration with the Mayo Clinic to develop foundation models for personalised medicine. Javier earned his degree in Computer Science from the University of Oviedo and completed his MSc at the University of Cambridge.

Kent is a consultant specialising in Clinical Oncology at West Suffolk NHS Foundation Trust and has experience running early-phase clinical trials, including PROCON (a phase I/II trial evaluating the use of carbogen and nicotinamide in conjunction with radiotherapy in the treatment of patients with high risk prostate cancer) and L-NNA (a phase I clinical trial sponsored by CRUK evaluating L-NNA as a cancer treatment). Kent has a BSc in Biochemistry and an MBBS in Medicine from Imperial College. He has nearly two decades of clinical oncology experience, working as a specialist registrar before qualifying as a consultant after being awarded an MD in Radiation Oncology from UCL.

John graduated from the University Hospital of Wales in 2001 and completed postgraduate training at Barts and The London in 2006. Appointed consultant clinical oncologist at St Bartholomew’s Hospital in 2014, he became Honorary Senior Lecturer at Barts Cancer Institute in 2025. He earned an MD(Res) from UCL in 2018 following radiotherapy research with the NCRI RTQA Group. John is Clinical Director for Thoracic Oncology, Radiotherapy Lead for HCA UK, and Oncology Clinical Lead for the NLCA. He specialises in lung and breast cancers, advanced systemic therapies, and cutting-edge radiotherapy, and is active in research, education, and community cancer initiatives.

David has held several leadership positions in healthcare technology over the past 20 years, including at Lightpoint Medical (acquired by Telix Pharmaceuticals), GE Healthcare and Novartis. He has a proven track record in technology development and commercialisation, from early-stage ventures to successful exits. He received a joint PhD from MIT and Harvard Medical School. David currently serves as a board chairman across a portfolio of medical device and digital health companies.

Tamera has over 15 years’ experience as a respiratory physician, including serving as Director of Interstitial Lung Disease (ILD) in the Department of Respiratory Medicine at the Royal Prince Alfred Hospital in Sydney. She trained in respiratory medicine at the University of New South Wales in Sydney and served as Clinical Fellow in ILD at the Royal Brompton Hospital in London with Professor Athol Wells, where she earned a PhD in the identification of pulmonary vascular dysfunction in ILD. She currently leads her Pulmonary Fibrosis research group at the University of Sydney. She is the lead investigator for the national Centre of Research Excellence for Pulmonary Fibrosis and Chair of the  Australasian Interstitial Lung Disease Registry.

Muhunthan has over 20 years experience in thoracic medicine and is a board-certified Pulmonologist. He qualified as a doctor from Imperial College London and undertook specialist medical training in Oxford where he was appointed as a member of the Royal College of Physicians. He was awarded a PhD in Molecular Immunology from Imperial College London before being appointed as a consultant physician. He was previously Director of Interstitial Lung Diseases at Royal Papworth and Addenbrooke’s Hospitals Cambridge UK and is currently an Honorary Associate Professor at the University of East Anglia.

Neil has over 25 years of experience in biopharma Finance and Business Development. Until 2023, he was a member of the Novartis Pharma Executive Committee and held several leadership positions at Novartis, most recently as Global Head of Business Development and Licensing. Prior to Novartis, he served as Chief Executive Officer and Chief Financial Officer at Medical Solutions plc, and previously as Chief Financial Officer at Pharmagene plc. Neil is currently a member of the Board of Directors at Galapagos NV. He holds a PhD and BSc in Molecular Biology/Microbiology from the University of Liverpool and is a qualified Chartered Accountant.

Patrick's extensive experience in leading finance and operations includes healthcare, biotech and engineering businesses in the UK and North America. His previous roles have included responsibility for building, managing and scaling all aspects of high-tech service, manufacturing, and research businesses from start-ups to listed companies, at VetCT Specialists, CN Bio Innovations and Johnson Matthey. Patrick holds a PhD in History from the University of Cambridge and is a Fellow of the ICAEW, having trained with Deloitte.

With more than 30 years’ experience in life sciences, including senior executive roles at major pharmaceutical companies such as Novartis, Roche and SmithKline Beecham, Debra has advanced multiple assets from first-in-human trials to global approval, across several disease areas. She specialises in translating science into sustainable enterprise value, helping boards and executive teams align innovation, governance and strategy, to deliver both patient impact and shareholder returns. Debra earned a Diploma in Pharmaceutical Medicine and received a MSc in Immunology from King’s College in London, and a Medical Degree from Queens’ College, Cambridge, UK. Debra is currently Chief Medical Officer of Centauri Therapeutics. 

Jennifer has an extensive background in the healthcare sector ranging from small not-for-profits to large corporations. She is currently CEO of Animalcare Group, where she has integrated separate business units to drive efficiency and growth. She also serves as a non-executive director of EKF Diagnostics, a global diagnostics and biotech company, and as a trustee for the Royal Brompton and Harefield Hospitals Charity, which is dedicated to improving the lives of people living with lung and heart diseases. Jennifer previously held senior commercial roles at AstraZeneca and GlaxoSmithKline, where her expertise ranged from product development and change management to marketing and communications. Jennifer holds a BSc in Physiology and Pharmacology from the University of Southampton.